Therapeutic opportunities in polyglutamine disease (Q34205521)

31 July 2017

1 reference

title

Therapeutic opportunities in polyglutamine disease (English)

1 reference

31 July 2017

Hughes RE

1

1 reference

31 July 2017

Olson JM

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

7

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

419-423

1 reference

Glutamine repeats and neurodegeneration

31 July 2017

cites work

1 reference

7 January 2021

Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.

1 reference

7 January 2021

Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro

1 reference

7 January 2021

Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone

1 reference

7 January 2021

Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease

1 reference

7 January 2021

Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract

1 reference

7 January 2021

Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils

1 reference

7 January 2021

Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans

1 reference

7 January 2021

Identification of genes that modify ataxin-1-induced neurodegeneration.

1 reference

7 January 2021

Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.

1 reference

7 January 2021

Genetic suppression of polyglutamine toxicity in Drosophila

1 reference

7 January 2021

Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease

1 reference

7 January 2021

Ubiquitin, cellular inclusions and their role in neurodegeneration

1 reference

7 January 2021

Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold

1 reference

7 January 2021

Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

1 reference

7 January 2021

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

1 reference

7 January 2021

A huntingtin-associated protein enriched in brain with implications for pathology

1 reference

7 January 2021

HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain

1 reference

7 January 2021

SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates

1 reference

7 January 2021

Huntingtin interacts with a family of WW domain proteins

1 reference

7 January 2021

Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation

1 reference

7 January 2021

Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin

1 reference

7 January 2021

Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells

1 reference

7 January 2021

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

1 reference

7 January 2021

CREB-binding protein sequestration by expanded polyglutamine

1 reference

7 January 2021

Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription

1 reference

7 January 2021

Transcriptional dysregulation in Huntington's disease

1 reference

7 January 2021

Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1.

1 reference

7 January 2021

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

1 reference

7 January 2021

Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea

1 reference

7 January 2021

Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

1 reference

7 January 2021

Replicating Huntington's disease phenotype in experimental animals

1 reference

7 January 2021

Oxidative stress, glutamate, and neurodegenerative disorders

1 reference

7 January 2021

Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum

1 reference

7 January 2021

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

7 January 2021

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

1 reference

7 January 2021

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

1 reference

7 January 2021

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

1 reference

7 January 2021

The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases

1 reference

7 January 2021

Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease

1 reference

7 January 2021

Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology

1 reference

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

7 January 2021

Inflammation and Alzheimer's disease

1 reference

7 January 2021

Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches.

1 reference

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

7 January 2021

The influence of huntingtin protein size on nuclear localization and cellular toxicity.

1 reference

7 January 2021

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract

1 reference

7 January 2021

Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells

1 reference

7 January 2021

Caspase-8 is required for cell death induced by expanded polyglutamine repeats.

1 reference

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

7 January 2021

Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects

1 reference

7 January 2021

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

1 reference

7 January 2021

Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila

1 reference

7 January 2021

Identifiers

DOI

10.1038/86486

1 reference

31 July 2017

1 reference